期刊文献+

吗替麦考酚酯和麦考酚钠用于肾移植后免疫抑制的药物经济学评价 被引量:5

Pharmacoeconomic Evaluation of Mycophenolate Mofetil and Enteric-coated Mycophenalate Sodium for Immuno-suppression after Renal Transplantation
原文传递
导出
摘要 目的:对吗替麦考酚酯和麦考酚钠用于肾移植后免疫抑制进行药物经济学评价。方法:基于社会视角,采用二次文献研究和模型研究方法,根据接受肾移植后患者健康状态发展规律,构建Markov模型,以成本效果比、成本效用比作为评价指标,并对结果进行敏感度分析。结果:在10个模型周期内,EC-MPS组肾移植患者获得的生命年和质量调整生命年分别为8.4年和6.1年,MMF组为7.5年和5.0年。EC-MPS组肾移植患者每获得一个生命年和质量调整生命年需付出的年医疗费用分别为47 936元和66 011元,MMF组为63 513元和95 270元。结论:EC-MPS用于肾移植后免疫抑制较MMF更具有成本效果。 Objective: To evaluate the cost-effectiveness of Mycophenolate mofetil and Enteric-coated Mycophenalate Sodium for immunosuppression after renal transplantation. Methods: The evaluation is based on social perspective. A markov model is constructed to simulate the development of the health status of patients after kidney transplantation. Cost-effectiveness ratio and cost-utility ratio are used as the evaluation indicators in the study. Sensitivity analysis is done to make sure that the conclusion is reliable. Results: Within ten cycles of the model, the life years and the quality-adjusted life year (QALY) of the EC-MPS group patient are 8.4 and 6.3 years respectively, and the MMF group patient are 7.5 and 3 years respectively. It costs 47 936 and 66 011 yuan to obtain every life year and every QALY for the patients of EC-MPS group, while the cost for patients of MMF group are 63 513 and 95 270 yuan respectively. Conclusion: The EC-MPS has more cost effectiveness than the MMF when is used for immunosuppression after renal transplantation.
出处 《中国卫生经济》 北大核心 2011年第3期94-96,共3页 Chinese Health Economics
关键词 肾移植 麦考酚钠 吗替麦考酚酯 药物经济学评价 马尔可夫模型 renal transplantation enteric-coated mycophenalate sodium mycophenolate mofetil pharmacoeconomic evaluation Markovian model
  • 相关文献

参考文献8

二级参考文献31

  • 1王平贤,龚桂芝,徐华英,黄赤兵,范明齐,张艮甫.慢性移植肾肾病与巨细胞病毒感染的相关性研究[J].临床内科杂志,2004,21(12):828-830. 被引量:4
  • 2李川江,于立新,邓文锋.两种免疫抑制方案在乙肝病毒感染的肾移植受者中的应用[J].临床泌尿外科杂志,2005,20(8):483-484. 被引量:6
  • 3李双海.公共项目投资评价的贴现率选择[J].财会月刊(中),2007(7):40-41. 被引量:4
  • 4国家发改委,建设部.建设项目经济评价方法与参数[M].第3版.北京:中国计划出版社,2006.
  • 5Zadrazil J, Horak P, Zahalkova J, et al. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to-tacrolimus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2009, 153(1) : 67.
  • 6Yu X, Zhang B, Xing C, et al. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation. Transplant Proc, 2008, 40 ( 10 ) : 3455.
  • 7SMITH D, GRAVELLE H. The practice of discounting economic evaluation of health care interventions. CHE Technical Paper Series 19( CENTRE FOR HEALTH ECONOMICS TECHNICAL PAPER SERIES) [ EB/OL]. [ 2000 - 10 ]. http://www, york. ac. uk/inst/che/pdf/tp 19. pdf.
  • 8CADTH. Guidelines for the Economic Evaluation of Health Technologies :Canada. 3^RD Edition [ EB/OL ]. [2006 - 03 - 21 ]. http :// www. cadth, ca/index, php/en/hta/reportspublications/search? keywords = Guidelines + for + the + economic + evalution + of + health + technologies% 3A + Canada.
  • 9KRAHN M, GAFNI A. Discounting in the economic evaluation of health care interventions [ J ]. Med Care, 1993,31 ( 5 ) :403 - 418.
  • 10Morales JM,Andres A,Rengel M,et al.Influence of cyclosporin,tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation[J].Nephrol Dial Transplant,2001,16(Suppl 1)∶121-124.

共引文献34

同被引文献48

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部